MARKETS
Markets

Sight Sciences Receives FDA 510(k) Clearance For OMNI Ultra Surgical System; Next-Generation Implant-Free MIGS Device For Primary Open-Angle Glaucoma

Aug 4, 2026 · 05:39 PM ET· updated 2h ago

Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform eye care and improve patients' lives, today

Share
Why It Matters

Sight Sciences got official permission from the FDA to sell a new eye surgery tool that helps people with a common type of glaucoma. This is a big checkpoint passed, so now watch if doctors start using it and if the company can actually sell it successfully.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.